Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Collegium Pharmaceutical Inc

COLL ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: BUY

Last Close

$28.23

▲ +0.28%

Market Cap $919.04M · Vol 240.03K

Key Metrics

P/E Ratio

22.99

FWD: 3.86

Market Cap

$919.04M

Small Cap

Div Yield

N/A

EPS Growth

+0.85%

YoY

RSI (14)

26.19

Momentum

Beta

0.70

vs Market

52W High

$50.00

43.54% below

52W Low

$25.47

10.84% above

Volume

240.03K

Avg 196.51K

P/B

4.87

Price-to-book

ROE

23.70%

Return on equity

Free Float

98.66%

Public shares

Shariah Compliance8 STANDARDS

✗ Collegium Pharmaceutical Inc (COLL) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does COLL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.21%

-19.39%

-18.95%

-38.35%

YTD

-39.03%

-24.03%

+18.61%

+59.04%

Financials & Valuation

TTM · Annual

Total Revenue	$780.57M
Net Income	$62.87M
Revenue Growth (YoY)	+6.32%
Gross Margin	59.35%
Operating Margin	23.97%
Net Profit Margin	8.05%
ROE	23.70%
ROA · ROIC	5.58% · 9.76%

P/E Ratio	22.99
Forward P/E (FY1)	3.86
PEG Ratio	-4.07
P/S	2.35
P/B	4.87
P/FCF	5.61
EPS Growth	+0.85%
Outstanding Shares	32.56M

Technical Indicators

50-Day SMA	$34.21
200-Day SMA	$39.11
RSI (14)	26.19
Beta	0.70
52-Week High	$50.00
52-Week Low	$25.47

Volume Today	240.03K
Avg Daily Volume (30D)	196.51K
Relative Volume	1.22x
Volatility (10D)	116.34
Volatility (30D)	72.79
Free Float	98.66%

Analyst Consensus

BUY

Current Price $28.23

Mean Target $52.33

52W Low$25.47 52W High$50.00

Current

Target

$25.47 $50.00

Current Analyst target

+85.38% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001T535S9

ISINUS19459J1043

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.